Myopharm is an IND stage biotechnology company focused on developing first in class, novel therapeutics for the treatment and prevention of Type 2 diabetes.
Myopharm is currently developing a number of diabetes therapeutics including a beta-cell-centric dual combination drug, to address the 50% antidiabetic treatment failures occurring in Type 2 diabetics.
Right now, there are no anti-inflammatory 'Beta-cell-centric' therapies on the market for Type 2 diabetes. Our novel & innovative beta-cell centric product, RK-01 or TriGlytza™ restored the efficacy of Metformin in C57BL/6J DIO mice with insulin resistance and pancreatic beta-cell dysfunction. We are on track to bring TriGlytza™ to market by 2027.
https://www.myopharm.com
Company Details
- Employees
- 5
- Address
- 60 Martin Pl, Levels 1,2&3,australia
- Industry
- Biotechnology
- Website
- myostin.com
- Keywords
- Biotechnology, Therapeutics, Orphan / Rare Diseases, metabolic diseases, diabetes, metabolic syndromes, T2D, R&D, type 2 Diabetes, Pre-Diabetes, Insulin Resistance, IND Approved, Beta-cell-centric, weightloss, endocrinology.
- HQ
- Sydney, New South Wales
Myopharm Limited Questions
Myopharm Limited's website is myostin.com
Myopharm Limited's LinkedIn profile is https://au.linkedin.com/company/myopharmltd
Myopharm Limited has
5 employees.
View email and phone details for 5
employees at Myopharm Limited.
Myopharm Limited's industry is
Biotechnology
Myopharm Limited's top competitors are
Actinogen Medical,
Telix Pharmaceuticals Limited,
Positron Ventures,
Syntro Health,
Scitech,
Blinklab Limited (Asx:bb1),
Ltr Pharma,
Evaris Pharma,
Percheron Therapeutics Limited,
Futurechemistry.
Myopharm Limited's categories are Biotechnology
